Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ALG-001
- Development stage
- Preclinical
- Lead developer
- Allegro
- Modality
- Hydrogel Systems → Drug Delivery Systems
- Administration
- Intraarticular
01
Overview
ALG-001 (Hydrocelin) is an injectable microparticle hydrogel developed as a treatment for osteoarthritis. It is designed to be administered via injection and functions as a hydrogel-based therapy, potentially providing cushioning or structural support within the joint. Preclinical studies have demonstrated positive safety results, with no signs of toxicity observed in animal models over periods of 4 and 13 weeks. The drug is being developed by Allegro and represents a novel approach to osteoarthritis management using biomaterial-based modalities rather than traditional small molecule or biologic drugs[1][2].
- Brand names
- Hydrocelin
- Other names
- Hydrocelin
Beyond the preview
Go deeper on ALG-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ALG-001.